Atossa Reports Q2 2026 Results, Highlights (Z)-Endoxifen Progress in Rare Diseases and Breast Cancer
ATOS sits 40% above its 52-week low of $1.7 on light trading volume (0.2× avg).
Summary
Atossa Therapeutics reported Q2 2026 financial results and provided a corporate update. The company highlighted new data presentations at AACR and ASCO, along with publications in peer-reviewed journals, supporting (Z)-endoxifen's potential in rare pediatric diseases like Duchenne Muscular Dystrophy and McCune-Albright Syndrome, as well as in breast cancer. The update follows a $4.1 million registered direct offering in June and a 10-Q filing today showing a cash balance of $26.1 million with a going concern warning. The clinical progress and upcoming H2 2026 data readouts are key for a company with limited cash runway.
At the time of this announcement, ATOS was trading at $2.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $1.70 to $19.35. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.